Seminars in Oncology Nursing
Volume 23, Issue 3 , Pages 162-173 , August 2007

Peripheral Neuropathy Related to Chemotherapy

  • Gail Wilkes

      Affiliations

    • Corresponding Author InformationAddress correspondence to Gail Wilkes, RNC, MS, ANP, AOCN®, 29 Rock Road, North Andover, MA 01845

References 

  1. Visovsky C, Daly BJ. Clinical evaluation and patterns of chemotherapy-induced peripheral neuropathy. J Am Acad Nurse Pract. 2004;16:353–359
  2. Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Invest. 2003;21:439–451
  3. Postma TJ, Heimans JJ, Muller MJ, et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998;9:739–744
  4. Dunlap B, Paice JA. Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol. 2006;4:398–399
  5. Wul FL, Brites C, Quevedo S, et al. Difference in the evaluation of symptoms between patients and their doctors in an oncologic hospital [abstr 2874] Proc Am Soc Clin Oncol 2002;21:264b.
  6. Varricchio CG, Bass E, Novotny P, et al. Common toxicity criteria versus symptom specific measures: how congruent are the data [abstr 2897]?. Proc Am Soc Clin Oncol. 2002;21:270b
  7. Stephens RJ, Hopwood P, Girling DJ, et al. Randomized trials with quality of life end points: are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings?. Qual Life Res. 1997;6:225–236
  8. Ostchega Y, Donohue M, Fox N. High-dose cisplatin-related peripheral neuropathy. Cancer Nurs. 1988;11:23–32
  9. Hay JW. Quality of life effects of chemotherapy-induced neuropathy in ovarian cancer. [abstr 886] Proc Am Soc Clin Oncol. 2002;21:222a
  10. Hausheer FH, Schilsky RL, Bain S, et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33:15–49
  11. Postma T, Heimans J. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2000;11:509–513
  12. Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2005;32:305–311
  13. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9–17
  14. Corse AM, Kunel RW. Peripheral neuropathy. In:  Barker LR,  Burton JR,  Zieve PD editor. Principles of ambulatory medicine. Ed 5. Baltimore, MD: Williams and Wilkins; 1999;p. 1296–1314
  15. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005;5(suppl 1):S38–S46
  16. Kuncl RW, George EB. Toxic neuropathies and myopathies. Curr Opin Neurol. 1993;6:695–704
  17. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chemo-modulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–147
  18. Eloxatin [package insert]. Bridgewater, NJ: sanofi-aventis US, LLC; 2006;August.
  19. Abraxane [package insert]. Schaumberg, IL: Abraxis Oncology; 2005;January.
  20. Johnson SA, Harper P, Hortobagyi GN, et al. Vinorelbine: an overview. Cancer Treat Rev. 1996;22:127–142
  21. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113–3120
  22. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24:4507–4514
  23. Mielke S, Mross K, Gerds TA, et al. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs. 2003;14:785–792
  24. de Gramont A, Boni C, Navaro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a medican follow-up of 4 years. [abstr 3501] J Clin Oncol. 2005;23(suppl):16S
  25. Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004;29:387–392
  26. Davis ID, Kiers L, MacGregor L, et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 2005;11:1890–1898
  27. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 2005;41:1746–1750
  28. Maestri A, DePasqualae Ceratti A, Cundari S, et al. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin- induced peripheral neuropathy. Tumori. 2005;91:135–138
  29. Gedlicka C, Sheithauer W, Schull B, et al. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. [letter] J Clin Oncol. 2002;20:3359–3361
  30. Hilpert F, Stahle A, Tome O, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy: a double-blind, placebo controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) ovarian cancer study group. Support Care Cancer. 2005;13:797–805
  31. Lorusso D, Ferrandine G, Greggi S, et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol. 2003;14:1086–1093
  32. Openshaw H, Beamon K, Synold TW, et al. Neurophysiological study of peripheral neuropathy after high dose paclitaxel. Clin Cancer Res. 2004;10:461–467
  33. Moore DH, Donnelly J, McGuire WP, et al. Limited access trial using amifostine for protection against cisplatin- and three hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:4207–4213
  34. Sevelda P, Sevelda U, Denison U, et al. Cytoprotection of amifostine (A) in ovarian cancer patients receiving paclitaxel/carboplatin (PC) first line chemotherapy in a multi-center phase III trial. [abstr 5021] J Clin Oncol. 2004;22(suppl4):254s
  35. Leong SS, Tan EH, Fong KW, et al. Randomized, double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small cell lung cancer. J Clin Oncol. 2003;21:1767–1774
  36. Gelmon K, Eisenhauer E, Bryce C, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol. 1999;17:3038–3047
  37. Socinski MA, Tynan M, Natoli S, et al. Phase III trial of paclitaxel (P), carboplatin (C) and amifostine in stage IV non-small cell lung cancer (NSCLC). [abstr 2015] Proc Am Soc Clin Oncol. 1999;1:303
  38. Gradishar WJ, Stephenson P, Glover DJ, et al. A phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188). Cancer. 2001;92:2517–2522
  39. Penz M, Kornek GV, Raderer M, et al. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. [letter] Ann Oncol. 2001;12:421–422
  40. Takeda K, Negoro S, Matsui K, et al. Phase I safety and pharmacokinetic trial of BNP7787 in patients receiving cisplatin (CDDP) and paclitaxel (PTX) for advanced non-small cell lung cancer (NSCLC) (An Osaka phase I study group trial). [abstr 453] Proc Am Soc Clin Oncol. 2002;19:114a
  41. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10:4055–4061
  42. Saif MW. Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J Appl Res. 2004;4:576–582
  43. Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20:1767–1774
  44. Eckel F, Schmelz R, Erdmann J, et al. Prevention of oxaliplatin induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. [abstr 579] Proc Am Soc Clin Oncol. 2001;20:146
  45. Lersch C, Schmelz R, Eckel F, et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2002;2:54–58
  46. Mariani G, Garrone O, Granetto C, et al. Oxaliplatin induced neuropathy: could gabapentin be the answer?. [abstr 2397] Proc Am Soc Clin Oncol. 2000;19:609a
  47. Wong GY, Michalak JC, Sloan JA, et al. A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: a North Central Cancer Treatment Group Study. [abstr] J Clin Oncol. 2005;23(suppl 16S):8001
  48. Marshall J, Zakari A, Hwang J, et al. Ginkgo biloba (GB) extract as a neuroprotective agent in oxaliplatin (Ox)-induced neuropathy (American Society of Clinical Oncologists Annual Meeting Proceedings). [abstr 3670] J Clin Oncol. 2004;22(suppl 14S):3670
  49. Vahdat L, Papdopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Cancer Clin Res. 2001;7:1192–1197
  50. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo controlled trial. J Clin Oncol. 2002;20:3478–3483
  51. Renno SI, Rao RD, Sloan J, et al. The efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase III randomized, double blind, placebo-controlled NCCTG trial, N01C3. [abstr A-8530] J Clin Oncol. 2006;24(suppl 18):475s
  52. Roberts JA, Jenison EL, Kim K, et al. A randomized, double-blind placebo controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol. 1997;67:172–177
  53. Koeppen S, Verstappen CCP, Korte R, et al. Lack of neuroprotection by an ACTH (4-9) analogue (A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma). Cancer Res Clin Oncol. 2004;130:153–160
  54. Durand JP, Brezault C, Goldwasser F. Protection against oxaliplatin acute sensory toxicity by venlafaxine. Anticancer Drugs. 2003;14:423–425
  55. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurol. 2005;64:26–31
  56. Cassidy J, Bjarnason GA, Hickish T, et al. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC) (2006 American Society of Clinical Oncologists Annual Meeting Proceedings Part I). [abstr] J Clin Oncol. 2006;24(suppl 18S):3507
  57. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24:1633–1642
  58. Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and cisplatin-induced neuropathy: a protective role of acetyl-L-carnitine. Clin Cancer Res. 2005;9:5756–5767
  59. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 1995;18:1160–1167
  60. Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895–2903
  61. Armstrong CM, Cota G. Calcium block of Na+ channels and its effect on closing rate Proc Natl Acad Sci U S A 1999;96:4145-4157.
  62. Boyle FM, Wheeler HR, Shenfield GM. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol. 1999;41:107–116
  63. Tredici G, Cavaletti G, Petruccioli MG, et al. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology. 1994;15:701–704
  64. Lecomte T, Landi B, Beaune P, et al. Glutathione S-tranferase P1 polymorphism (IIe105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res. 2006;12:3050–3056
  65. Guay DR. Adjunctive agents in the management of chronic pain. Pharmacotherapy. 2001;21:1070–1081
  66. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57:505–509
  67. Apfel SC, Scwartz S, Bruce T. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. JAMA. 2000;284:2215–2221
  68. van der Hoop RG, Vecht CJ, van der Burg ME, et al. An ACTH-(4-9) analog prevents cisplatin-induced neuropathy in ovarian cancer patients. N Engl J Med. 1990;332:89–94
  69. Davis JL, Smith RL. Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules. Diabetes Care. 1999;22:1909–1910
  70. Viscovsky C. Measuring oncology nursing-sensitive patient outcomes: evidence-based summary. Available at: http://onsopcontent.ons.org/toolkits/evidence/Clinical/pdf/NeuropathySummary.pdf. (accessed November 23, 2006).
  71. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-A GERCOR study. J Clin Oncol. 2006;24:394–400
  72. Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: phase III study of weekly paclitaxel via 1-hour (h) infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2 normal MBC. [abstr 512] Proc Am Soc Clin Oncol. 2004;22:6s
  73. Gelderblom H, Mross K, ten Tije AJ, et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol. 2002;20:574–581
  74. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimens. Eur J Cancer. 2006;42:24–30
  75. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol. 1998;16:3353–3361
  76. Wong R, Sagar S. Acupuncture treatment for chemotherapy-induced peripheral neuropathy. Acupunct Med. 2006;24:87–91

PII: S0749-2081(07)00051-4

doi: 10.1016/j.soncn.2007.05.001

Seminars in Oncology Nursing
Volume 23, Issue 3 , Pages 162-173 , August 2007

Article Tools